Premia Spine
Tel Aviv, Israel· Est.
Premia Spine offers an injectable, cell‑laden scaffold to regenerate degenerated spinal discs, targeting the large unmet need in low‑back pain treatment.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $30M
AI Company Overview
Premia Spine offers an injectable, cell‑laden scaffold to regenerate degenerated spinal discs, targeting the large unmet need in low‑back pain treatment.
Spinal DisordersOrthopedics
Technology Platform
Injectable hydrogel scaffold delivering autologous MSCs and growth factors to regenerate intervertebral disc tissue.
Opportunities
An aging population and high unmet need for biologic disc regeneration present a multi‑billion‑dollar market opportunity for minimally invasive therapies.
Risk Factors
Regulatory approval uncertainty, demonstration of long‑term efficacy, and competition from established surgical devices could impede commercialization.
Competitive Landscape
Competitors such as DiscGenics and Spineart focus on cell‑based injections, but Premia differentiates through its proprietary scaffold that provides mechanical support and sustained biologic delivery.